Strengthened international presence through the opening of new European affiliates (Germany and Spain), consolidating direct operations in key strategic markets and successfully delivering the launch of sugemalimab.

Strategic agreement with CStone Pharmaceuticals to commercialize sugemalimab in key Western European markets, strengthening the oncology portfolio in lung cancer, alongside the transfer of a pediatric product from Primex Pharmaceuticals to Gentili Pharma.

Consolidation of the pain portfolio and expansion across Europe through an agreement with Takeda for the global rights to fentanyl-based products, leading to the establishment of Gentili Pharma to support international growth.

Strengthened the product portfolio through a strategic agreement with Novartis Italia, marking the company’s entry into rare diseases field and establishing a presence in a highly specialized therapeutic area.

Expansion of commercial activities and development of new partnerships in multiple therapeutic areas. Istituto Gentili becomes product owner within breast cancer area and supportive care focused in malnutrition.

Development of the product portfolio which marked the first step in the company’s growth, building a comprehensive portfolio focused on onco-hematology, pain therapy, and supportive care, enabled through a strategic deal with Teva OncoCare.

Establishment of  Istituto Gentili as an independent pharmaceutical family company, born by his founder vision to create a flexible company model focused on the valorization of innovative therapeutic solutions in oncology.